Searchable abstracts of presentations at key conferences in endocrinology

ea0070aep885 | Thyroid | ECE2020

Clinical severity score (CSS) and graves’ recurrent events after therapy (GREAT) score could predict radioiodine efficacy for treatment of Graves’ disease relapse

Repaci Andrea , Beleffi Michelle , Salituro Nicola , Colapinto Alessandra , Vicennati Valentina , Pelusi Carla , Altieri Paola , Gambineri Alessandra , Di Dalmazi Guido , Pagotto Uberto

Background: Antithyroid drugs (ATDs) are the first line treatment for Graves’ disease in Europe and Asia. However, their long term-efficacy is doubtful, with a high disease relapse rate after discontinuation. Radioiodine and surgery can be used as a second line therapy as definitive approaches after ATDs failure. In recent years, the GREAT and the CSS scores have been suggested to assess the risk of relapse at the time of disease onset, but no data are available about th...

ea0081rc3.4 | Rapid Communications 3: Thyroid 1 | ECE2022

Are BRAF-TERT mutated differentiated thyroid cancers similar to other double mutated?

Colapinto Alessandra , Basso Cristina , Vicennati Valentina , Cavicchi Ottavio , Lodi Rizzini Elisa , Golemi Arber , Tabacchi Elena , Nannini Margherita , De Biase Dario , De Leo Antonio , Tallini Giovanni , Pagotto Uberto , Repaci Andrea

Introduction: Differentiated thyroid cancers (DTCs) carrying BRAF and TERT mutations are associated with high-risk clinicopathological features and poor prognosis. However, there are currently no studies comparing BRAF-TERT tumors to other double mutated DTCs.Aim: To verify whether BRAF-TERT mutated DTCs differ from other double mutated DTCs in terms of clinicopathological characteristics and outcome.Materials and Methods: 168 DTCs...

ea0081rc3.5 | Rapid Communications 3: Thyroid 1 | ECE2022

Impact of stimulated thyroglobulin and BRAF status in Stage I and ATA intermediate risk DTC

Basso Cristina , Colapinto Alessandra , Vicennati Valentina , Pagotto Uberto , Tallini Giovanni , De Leo Antonio , De Biase Dario , Lodi Rizzini Elisa , Cavicchi Ottavio , Nannini Margherita , Tabacchi Elena , Golemi Arber , Repaci Andrea

Introduction: There is no clear indication for radioiodine treatment (RAI) in patients affected by differentiated thyroid cancer (DTC) in Stage I and ATA intermediate risk, according to American Thyroid Association (ATA) guidelines.Purpose: Our aim is to evaluate whether integration of BRAF status and thyroglobulin TSH-stimulated at the time of RAI (A-HTg) could further improve accuracy of stratification, and therefore therapeutic management, in DTC pati...

ea0090p757 | Thyroid | ECE2023

68Ga-PSMA-PET vs 18F-FDG-PET in metastatic radio-refractory differentiated thyroid cancers

Colapinto Alessandra , Basso Cristina , Vicennati Valentina , Fanti Stefano , Tabacchi Elena , Golemi Arber , Calderoni Letizia , Vetrone Luigia , Lodi Rizzini Elisa , Nannini Margherita , De Biase Dario , Tallini GIovanni , Pagotto Uberto , Repaci Andrea

Introduction: Although 18F-FDG-PET has found wide application in the management of radio-refractory differentiated thyroid cancers (RAI-R-DTCs), alternative radiotracers, including 68Ga-PSMA have been recently evaluated. Prostate-specific membrane antigen (PSMA) is in fact overexpressed in the microvasculature of several solid malignancies including thyroid cancers.Aim: To compare the diagnostic performance between 68Ga-P...